Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-007240
Filing Date
2025-01-28
Accepted
2025-01-28 08:00:31
Documents
3
Period of Report
2025-01-28

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0228867-6k_nlsphar.htm 6-K 10353
2 PRESS RELEASE TITLED: "NLS PHARMACEUTICS ANNOUNCES THE LAUNCH OF A PRECLINICAL P ea022886701ex99-1_nlsphar.htm EX-99.1 32218
3 GRAPHIC ex99-1_001.jpg GRAPHIC 9458
  Complete submission text file 0001213900-25-007240.txt   56785
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 25560988
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)